| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0733-8635(05)70228-X |
| P698 | PubMed publication ID | 11155585 |
| P2093 | author name string | Moossavi M | |
| Scher RK | |||
| Bagheri B | |||
| P2860 | cites work | Terbinafine-induced lupus erythematosus | Q74700721 |
| Adverse drug reactions of the new oral antifungal agents--terbinafine, fluconazole, and itraconazole | Q74726547 | ||
| Serum sickness-like reaction to itraconazole | Q77588507 | ||
| Oral treatment of ringworm with griseofulvin | Q78483091 | ||
| Single dose therapy of tinea capitis | Q79241490 | ||
| Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption | Q79372640 | ||
| Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes | Q24563412 | ||
| Overview of medically important antifungal azole derivatives | Q24617248 | ||
| Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole | Q28272304 | ||
| Terbinafine: mode of action and properties of the squalene epoxidase inhibition | Q28284524 | ||
| Treatment of Candida nail infection with terbinafine | Q28299342 | ||
| Pharmacology of the allylamines | Q28331802 | ||
| Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes | Q28360287 | ||
| Ketoconazole-induced fulminant hepatitis | Q28362556 | ||
| Thrombocytopenia caused by fluconazole therapy | Q33490551 | ||
| Treatment of tinea capitis: beyond griseofulvin | Q33657966 | ||
| Drug interactions with itraconazole, fluconazole, and terbinafine and their management | Q33699931 | ||
| In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis | Q33729638 | ||
| Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. A review of the literature | Q33811501 | ||
| Absorption, Distribution, Metabolism, and Excretion of Griseofulvin in Man and Animals | Q34078698 | ||
| The rise and fall of fluorescent tinea capitis | Q34266052 | ||
| Alopecia associated with fluconazole therapy | Q34301322 | ||
| Terbinafine in onychomycosis with involvement by non-dermatophytic fungi | Q34341344 | ||
| Anti-inflammatory properties of griseofulvin | Q43605508 | ||
| Loss of taste and terbinafine | Q43609515 | ||
| Fluconazole-induced jaundice | Q43702524 | ||
| Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). | Q43988924 | ||
| Systemic antifungal agents used to treat onychomycosis | Q44032641 | ||
| Fluconazole levels in human epidermis and blister fluid | Q44130038 | ||
| Itraconazole in the treatment of tinea capitis | Q44217703 | ||
| Itraconazole in Antifungal Therapy | Q44230470 | ||
| Treatment of kerion with fluconazole | Q44382036 | ||
| Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy | Q44683494 | ||
| Itraconazole in the management of chronic dermatophytosis. | Q44833787 | ||
| Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children | Q44835069 | ||
| Stevens-Johnson syndrome after fluconazole | Q44958291 | ||
| Drugs recently released in Belgium. Filgrastim--terbinafine | Q45145488 | ||
| Fluconazole for the treatment of tinea capitis in children | Q45280065 | ||
| A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis | Q45297017 | ||
| Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection | Q45777061 | ||
| Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations | Q46010998 | ||
| Adverse events associated with itraconazole in 189 patients on chronic therapy. | Q46013419 | ||
| New therapies for onychomycosis | Q46551141 | ||
| One-week therapy with oral terbinafine in cases of tinea cruris/corporis | Q46731129 | ||
| Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones | Q46740288 | ||
| Effect of particle size on blood griseofulvin-levels in man. | Q47427973 | ||
| Antimitotic Action of Griseofulvin does not Involve Disruption of Microtubules | Q48642819 | ||
| Effect of feeding on bioavailability of griseofulvin in children. | Q51647807 | ||
| Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. | Q51803060 | ||
| Griseofulvin inhibits Fungal Mitosis | Q53705508 | ||
| Itraconazole: pharmacologic studies in animals and humans. | Q53883577 | ||
| Ketoconazole Blocks Adrenal Steroid Synthesis | Q53911940 | ||
| Investigation of terbinafine as a CYP2D6 inhibitor in vivo. | Q53931768 | ||
| An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis | Q54067663 | ||
| Induction of fluconazole metabolism by rifampin: in vivo study in humans. | Q54079254 | ||
| Oral ketoconazole in cutaneous fungal infections. | Q54133692 | ||
| Hepatic injury associated with itraconazole. | Q55037189 | ||
| Oral antifungal agents for onychomycosis | Q58404901 | ||
| Experimental Ringworm in Guinea Pigs: Oral Treatment with Griseofulvin | Q59068288 | ||
| Griseofulvin for eosinophilic fasciitis | Q61628582 | ||
| Pityrosporum folliculitis and ketoconazole | Q67242531 | ||
| Ketoconazole therapy for fungal urinary tract infections | Q67268907 | ||
| Safety of fluconazole in women taking oral hypoglycaemic agents | Q67513222 | ||
| Ciclosporin A and Griseofulvin: Another Drug Interaction | Q67901617 | ||
| Fluconazole-nortriptyline drug interaction | Q67980486 | ||
| Special features of the clinical use of oral terbinafine in the treatment of fungal diseases | Q68068780 | ||
| Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge | Q68075041 | ||
| Determination of terbinafine in nail samples during systemic treatment for onychomycoses | Q68443350 | ||
| Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole | Q68483964 | ||
| A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris | Q68523004 | ||
| Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial | Q68586321 | ||
| Fluconazole-induced thrombocytopenia | Q68603909 | ||
| Are laboratory studies necessary for griseofulvin therapy? | Q68853743 | ||
| Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin | Q69087910 | ||
| New antifungal agents | Q69353109 | ||
| Griseofulvin: Immunosuppressive Action | Q69384389 | ||
| Pityriasis versicolor with ketoconazole | Q69500157 | ||
| Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis | Q69559928 | ||
| Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer | Q69971320 | ||
| Pityrosporum, ketoconazole, and seborrheic dermatitis | Q70034594 | ||
| Tinea capitis caused by Trichophyton tonsurans | Q70095414 | ||
| Mechanisms of action of the antimycotic imidazoles | Q70154156 | ||
| Griseofulvin levels in stratum corneum. Study after oral administration in man | Q70441266 | ||
| Fluconazole-cyclosporine interaction: a dose-dependent effect? | Q70668575 | ||
| The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans | Q70766721 | ||
| Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study | Q71260062 | ||
| Thrombocytopenia caused by fluconazole | Q71260155 | ||
| Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics | Q71361343 | ||
| Tinea capitis | Q71567328 | ||
| An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis | Q71593625 | ||
| Itraconazole-induced acute generalized exanthemic pustulosis | Q71847673 | ||
| Oral terbinafine and erythema multiforme | Q72050482 | ||
| Fatal acute hepatic necrosis due to fluconazole | Q72066409 | ||
| Stevens-Johnson syndrome after terbinafine therapy | Q72255223 | ||
| Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective | Q72426588 | ||
| Ketoconazole and cyclosporin | Q72539860 | ||
| Hepatic reactions during ketoconazole treatment | Q72543012 | ||
| Ketoconazole therapy for advanced prostate cancer | Q72586561 | ||
| Ketoconazole for prostate cancer | Q72587207 | ||
| An epidemic of infection with Trichophyton tonsurans revealed in a 20-year survey of fungal infections in Chicago | Q72779696 | ||
| Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences | Q72793332 | ||
| A fluconazole/amitriptyline drug interaction in three male adults | Q73255326 | ||
| Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial | Q73874830 | ||
| Once-weekly fluconazole in the treatment of onychomycosis: introduction | Q74666793 | ||
| Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail | Q74666798 | ||
| Black piedra: the first case treated with terbinafine (Lamisil). | Q34341348 | ||
| Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin | Q34487267 | ||
| Interaction between oral contraceptives and griseofulvin. | Q34549044 | ||
| Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes | Q34693201 | ||
| The response of seborrhoeic dermatitis to ketoconazole | Q34706999 | ||
| Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. | Q34707516 | ||
| Influence of food on the pharmacokinetics of ketoconazole | Q34708495 | ||
| Azole Antifungal Agents | Q35227084 | ||
| Azole antifungal agents: emphasis on new triazoles | Q35287663 | ||
| Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses | Q35312015 | ||
| Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications | Q35331234 | ||
| Adverse drug reactions to systemic antifungals. Prevention and management | Q35453449 | ||
| Itraconazole pharmacokinetics in patients with renal dysfunction | Q35564534 | ||
| Orally administered ketoconazole: route of delivery to the human stratum corneum | Q35755582 | ||
| Pharmacokinetics of terbinafine in the nail | Q35866620 | ||
| Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism | Q36093518 | ||
| Nortriptyline intoxication induced by terbinafine. | Q37150468 | ||
| Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. | Q37894392 | ||
| Treatment of oral candidosis with itraconazole: a review | Q37894395 | ||
| Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses | Q37941066 | ||
| Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses | Q38269547 | ||
| Global overview of Lamisil. | Q38568534 | ||
| In vitro activity of terbinafine | Q38738790 | ||
| Clinical pharmacokinetics of terbinafine (Lamisil). | Q38738795 | ||
| Studies in the biochemistry of micro-organisms: Griseofulvin, C(17)H(17)O(6)Cl, a metabolic product of Penicillium griseo-fulvum Dierckx | Q39332008 | ||
| Clinical pharmacokinetics of ketoconazole | Q39633274 | ||
| The use of ketoconazole as an inhibitor of steroid production | Q39667196 | ||
| Effects of griseofulvin on the morphology, growth and metabolism of fibroblasts in culture | Q39865992 | ||
| Antifungal agents: an overview. Part II. | Q40449449 | ||
| Current therapy of dermatophytosis. | Q40697959 | ||
| Itraconazole: a new triazole antifungal agent | Q40701443 | ||
| Pharmacokinetic drug interactions with antimicrobial agents | Q40720380 | ||
| Fluconazole-induced symptomatic phenytoin toxicity | Q40748053 | ||
| Pharmacokinetic optimisation of oral antifungal therapy | Q40791120 | ||
| Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases | Q40812137 | ||
| Kinetics and spectrum of activity of oral antifungals: the therapeutic implications | Q40817808 | ||
| Pediatric antifungal therapy | Q40846560 | ||
| Onychomycosis. Agents of choice. | Q40851599 | ||
| Clinical pharmacokinetics of fluconazole | Q40884105 | ||
| Dermatophytosis of the feet | Q41121083 | ||
| Recent developments in antifungal therapy | Q41121162 | ||
| Oral antifungal drug interactions | Q41504422 | ||
| Fluconazole-induced congenital anomalies in three infants | Q42553585 | ||
| Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. | Q43433505 | ||
| Response of the cutaneous lesions of Reiter's syndrome to ketoconazole | Q43504119 | ||
| Therapy with fluconazole for tinea corporis, tinea cruris, and tinea pedis | Q43523157 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 35-52 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Dermatologic Clinics | Q15758379 |
| P1476 | title | Systemic antifungal therapy | |
| P478 | volume | 19 |
| Q64075693 | Clinico-mycological profile of tinea capitis and its comparative response to griseofulvin versus terbinafine |
| Q35129027 | Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor |
| Q24562833 | Dermatology for the practicing allergist: Tinea pedis and its complications |
| Q38085729 | Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review |
| Q35079824 | Important drug interactions and reactions in dermatology |
| Q33370108 | Pityriasis lichenoides and idiopathic thrombocytopenic purpura in a young girl |
| Q35131539 | Protothecosis. |
| Q68453596 | The Role of Percutaneous Nephrostomy in the Management of Obstructing Candidiasis of the Urinary Tract in Infants |
| Q35548321 | Tinea corporis in human immunodeficiency virus‐positive patients: case report and assessment of oral therapy |
Search more.